Skip to contentL
Lexicon Pharmaceuticals, Inc.
L
LXRXLexicon Pharmaceuticals, Inc. Q4 2024 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$1.55M$1.55Mderived+131.0% vs Q4 2023 Net Income-$33.77M-$33.77MderivedN/M vs Q4 2023 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Lexicon Pharmaceuticals, Inc. · CIK 1062822 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived-$32,737,000N/M Operating Cash Flowderived-$21,491,000N/M Free Cash Flowderived-$21,965,000N/M Margins · derivedOperating margin-2112.1%+4853.2 pt vs Q4 2023
Net margin-2178.5%+5236.7 pt vs Q4 2023
ended Dec 31, 2024 · filed Mar 7, 2025 · 66 d after period end